By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Gilead Sciences, Inc. 

333 Lakeside Drive

Foster City  California  94404  U.S.A.
Phone: 800-GILEAD-5 or 650-574-3000 Fax: 650-522-5800


Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.




CEO: John F. Milligan, PhD

Chief Scientific Officer: Norbert W. Bischofberger, PhD

CFO: Robin L. Washington

COO: Kevin Young


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: Gilead
Employees: 4,000
Symbol: GILD

Company News
Why Gilead (GILD) Might Not Make an Oncology Buy After All 8/16/2017 5:45:48 AM
Gilead (GILD) to Unveil New SoCal Facility That Could House Up to 500 Employees 8/16/2017 5:23:12 AM
Why Gilead (GILD) Might Do 'Nothing In Oncology' As Key Drugs Topple 8/11/2017 8:17:21 AM
Gilead (GILD)'s HIV Triple Combo Gets Sped-up FDA Review, Decision Date Locked Down 8/11/2017 6:48:36 AM
Is AbbVie (ABBV) About to Deliver a Blow to Gilead (GILD)' Guidance? 8/7/2017 9:22:22 AM
Gilead (GILD) Release: U.S. FDA Approves Expanded Labeling For Epclusa (Sofosbuvir/Velpatasvir) For The Treatment Of Chronic Hepatitis C In Patients Co-Infected With HIV 8/2/2017 7:22:53 AM
5 Things Gilead (GILD)'s Q2 Earnings Numbers Didn't Tell You 8/1/2017 6:03:07 AM
European Commission (EC) Grants Marketing Authorization For Gilead (GILD)’s Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) For The Treatment Of All Genotypes Of Chronic Hepatitis C 7/28/2017 6:11:41 AM
Gilead (GILD) Announces Second Quarter 2017 Financial Results 7/27/2017 7:51:14 AM
Gilead (GILD) Announces Third Quarter 2017 Dividend 7/27/2017 7:48:54 AM